Edgewise Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
EWTX$48.74+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
STATEMENTS OF CASH FLOWS
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended December 31, | ||||||
| · 2024 · 2023 | ||||||
| Cash flows from operating activities · · · · · | ||||||
| Net loss | | $(133,813) | $(100,163) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | |||
| Depreciation | | | 2,069 | | 1,551 | |
| Stock-based compensation | | 24,712 | | 17,560 | ||
| Accretion of discount on marketable securities, net | | | (12,545) | | | (9,517) |
| Amortization of right-of-use asset | | | 221 | | | 181 |
| Changes in assets and liabilities: | | | | |||
| Prepaid expenses and other assets | | 3,292 | | (3,553) | ||
| Accounts payable | | 1,737 | | (92) | ||
| Accrued compensation | | 4,361 | | 1,663 | ||
| Accrued other expenses and other liabilities | | 1,158 | | 526 | ||
| Lease liability | | (220) | | | (104) | |
| Net cash used in operating activities | | (109,028) | | | (91,948) | |
| | | | | | | |
| Cash flows from investing activities | | | | | ||
| Purchases of marketable securities | | (477,055) | | (255,866) | ||
| Sales of marketable securities | | | 15,794 | | | 20,118 |
| Maturities of marketable securities | | | 277,917 | | | 344,379 |
| Purchases of property and equipment | | (1,312) | | (5,745) | ||
| Net cash (used in) provided by investing activities | | (184,656) | | 102,886 | ||
| | | | | | | |
| Cash flows from financing activities | | | ||||
| Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering costs | | | 239,147 | | | 52,618 |
| Exercise of stock options | | 9,480 | | 117 | ||
| Payment of deferred offering costs | | | (262) | | | (165) |
| Proceeds from Employee Stock Purchase Plan | | | 888 | | | 596 |
| Net cash provided by financing activities | | 249,253 | | 53,166 | ||
| | | | | | | |
| Net change in cash and cash equivalents | | (44,431) | | 64,104 | ||
| Cash and cash equivalents at beginning of period | | 86,097 | | 21,993 | ||
| Cash and cash equivalents at end of period | | $41,666 | | $86,097 | ||
| Supplemental disclosures of non-cash investing and financing activities: | | | ||||
| Right-of-use asset obtained in exchange for new operating lease liability, net of tenant improvement receivable | | $— | | $1,110 | ||
| Property and equipment purchases included in accounts payable and accrued other expenses | | $44 | | $227 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.